Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Non Operating Investment Income (2010 - 2014)

Fennec Pharmaceuticals posted quarterly Non Operating Investment Income of -$30000.0 for Q4 2014, up 98.67% year-on-year from -$15100.5 in Q4 2013, and down 107.92% on a QoQ basis from $379000.0 in Q3 2014.

Fennec Pharmaceuticals (FENC) has 5 years of Non Operating Investment Income data on file, last reported at -$30000.0 in Q4 2014.

  • For the quarter ending Q4 2014, Non Operating Investment Income rose 98.67% year-over-year to -$30000.0; the trailing twelve-month figure through Dec 2015 stood at $349000.0 (up 116.42% YoY), and the FY2014 full-year result was $349000.0, changed N/A from the prior year.
  • Non Operating Investment Income for Q4 2014 stood at -$30000.0, down from $379000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $7.5 million in Q2 2013 and bottomed at -$5.7 million in Q4 2010.
  • The 5-year median for Non Operating Investment Income is -$30000.0 (2014), against an average of -$207000.0.
  • Peak annual rise in Non Operating Investment Income reached 1068.22% in 2013, while the deepest fall reached 1128.78% in 2013.
  • A 5-year view of Non Operating Investment Income shows it stood at -$5.7 million in 2010, then soared by 176.33% to $4.4 million in 2011, then sank by 222.95% to -$5.4 million in 2012, then surged by 58.22% to -$2.3 million in 2013, then surged by 98.67% to -$30000.0 in 2014.
  • The last three Non Operating Investment Income figures came in at -$30000.0 (Q4 2014), $379000.0 (Q3 2014), and $181000.0 (Q2 2014), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 235,807.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 230,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Fennec Pharmaceuticals 281.48 Mn 244.70 Mn 7.67 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2014 -30,000.00
Dec 31, 2014 -30,000.00
Sep 30, 2014 379,000.00
Sep 30, 2014 379,000.00
Jun 30, 2014 181,000.00
Jun 30, 2014 181,000.00
Mar 31, 2014 -2.66 Mn
Mar 31, 2014 -2.66 Mn
Dec 31, 2013 -2.25 Mn
Dec 31, 2013 -2.25 Mn
Sep 30, 2013 -1.71 Mn
Sep 30, 2013 -1.71 Mn
Jun 30, 2013 7.54 Mn
Jun 30, 2013 7.54 Mn
Mar 31, 2013 -3.57 Mn
Mar 31, 2013 -3.57 Mn
Dec 31, 2012 -5.40 Mn
Dec 31, 2012 -5.40 Mn
Sep 30, 2012 -139,000.00
Sep 30, 2012 -139,000.00
Jun 30, 2012 645,000.00
Jun 30, 2012 645,000.00
Mar 31, 2012 3.33 Mn
Mar 31, 2012 3.33 Mn
Dec 31, 2011 4.39 Mn
Dec 31, 2011 4.39 Mn
Sep 30, 2011 -2.22 Mn
Sep 30, 2011 -2.22 Mn
Jun 30, 2011 225,000.00
Jun 30, 2011 225,000.00
Mar 31, 2011 613,000.00
Mar 31, 2011 613,000.00
Dec 31, 2010 -5.75 Mn
Dec 31, 2010 -5.75 Mn
Sep 30, 2010 2.57 Mn
Sep 30, 2010 2.57 Mn
Jun 30, 2010 -72,000.00
Jun 30, 2010 -72,000.00